{
  "doc_id": "Determina_33-2024_Lumykras",
  "created_date": "2024",
  "country": "IT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "AG FA DET Ricl dell (Det (OJ Vi corre modi l'Ag disp Serv Vi salu dello sull farm sett nine genn Mini pubblici genn Vi dello pubblica Gazz GENZIA ITALIANA DEL ARMACO TERMINA 17 May 2024 lassification of the medicinal product for human use (Lumykras) pursuant to Article 8 (10) of Law No 537 of 24 December 1993, ending No 33/2024). (24A02603) U No 121 of 25-5-2024)",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "THE CHAIRMAN is Art. 48 of Decree-Law No 269 of 30 September 2003,",
      "text": "Before 24 November 2003, no. 326, which established Italian drug genzia and, in particular, paragraph 33, which places the negotiation of the price for products reimbursed by the national health defect between the Agency and producers; in accordance with art. 48, paragraph 13, of Decree-Law 30 November 2003, No. 269, converted, with amendments, by Law 24 November 2003 n. 326 1/5 Having regard to the decree of the Minister of Health of 5 April 2024 with which, from the date of the same, Professor Robert Giovanni Nistico' was appointed president of the board of directors of the Italian Agency of the drug, pursuant to art. 7 of the aforementioned decree of 20 September 2004, n. 245 and subsequent modifications; having regard to a decree of 9 February 2024 of the Ministry of Health appointing Dr. Pierluigi Russo as technical-scientific director of the italian Agency of medicine, in accordance with art. 10-bis of the cited decree of 21 September 2004, no. 245 as successive amendments; having seen the decision of the general manager n. 643 of 28 May 2020 with which he was conferred to Dr. Decree of the Minister of Health of 20 September 2004, n. 245 and subsequent amendments; having regard to the decision of the Director-General n. 643 of 28 May 2020 with which Dr. Trotta Francesco was appointed as manager of the HTA sector and the economy of the drug; Having regard to Law n. 537 of 24 December 1993 on corrective measures for public finances, with particular reference to Article 8 (10), which provides for the classification of medicinal products payable by the National Health Service; Having respect to Law N. 376 of 14 December 2000 on health protection of sporting activities and the fight against doping; Having regards to Article 48, paragraph 33-ter of Decree-Law n. 269 of 30 September 2003, converted, with amendments, by Law nÂ° 326 of 24 November 2003, in the field of specialties for medicinal products subject to refundability conditional in the framework of the AIFA monitoring registers; In view of Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products, amending Directive 2001/83/EC and Regulation (CE) n. Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 establishing Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing the European Medicines Agency; - No 227 of 29 September 2006; Having regard to the Decision OF AIFA No 49/2022 of 1 April 2022, published in the Official Journal of the Italian Republic - General Series No 109 of 11 May 2022, containing \"Classification', pursuant to Article 12 (5) of Law No 189 of 8 November 2012, of the medicinal product for human use \"Lumykras', approved by centralized procedure (sotorasib); In view of the official documents; Determines: Classification for the purposes of refundability The medicinal product LUMYKRAS (sotorasib) in the packages listed below is classified as follows: Therapeutic indications subject to negotiation: Packaging: (PVC/PE/PVDC/alu) - 240 tablets - A.I.C. No 049858018/E (base 10) - Refundability class: H - ex factory price (excluding VAT) euro 7.368,00 - public price (incl. VAT) Euro 12160,24; Compulsory discount on the ex factory price, to be paid to public health facilities, including private health facilities accredited with the National Health Service, as under negotiated conditions. The company, subject to the provisions on disposal of stocks, in compliance with art. 13 of Decree-Law 30 April 2019, No 35, converted, with amendments, in law 25 June 2019, no 60, undertakes to maintain a constant supply adapted to the requirements of the National health service. Validity of the contract: 24 months. Terms and conditions of use A register is established dedicated to the monitoring of the use of the medicinal product \"Lumykras\" (sotorasib), based on sotorasib, for the indication allowed for the refundability': For the purpose of the prescription and dispensation of the medicine, doctors and pharmacists related to the user centers specifically identified by the regions will have to fill out the data collection data available against access through the institutional website of the AIFA, at the web address The doctors and chemists authorized to access the monitoring register AIFA must carry out the prescription of the medication in accordance with the criteria of eligibility and prescriptive appropriateness reported in the documentation consultable on the institutional portal of the AIDA: In case of temporary impediment of access to the information systems, the authorized doctors and pharmacists must guarantee the treatment from the date of entry into force of the present determines. After availability of the computer functions, the doctors and the pharmacists will in any case have to insert data of the treatments carried out on the aforementioned web platform. Following the availability of computer functions, doctors and pharmacists will in any case have to enter the data of the treatments carried out in the aforementioned web platform. Cla La classificazi \"Lumykras\" (average prescription for sale to the public specialists - onco This publication in the will be notified for placing in Rome, 17 maggi asification for the purpose of supplying ion for the purposes of supply d rasib) is the following: medicinal product ica limitiva, to be renewed volt lico on prescription of osp ologos (NRL). Final provisions hermina has taken effect from the day following the Official Journal of the Republic to the company's owner of the trade. i 2024 The takings a/series_general/original to the medicine and subject at a time, pedaliers or desive to its Italian ica and the authorization: Nistico'",
      "start_page": 1,
      "end_page": 5
    }
  ],
  "_translation_metadata": {
    "processing_timestamp": "2025-08-07T13:13:12.300304",
    "source_file": "Determina_33-2024_Lumykras_cleaned.json",
    "detected_language": "it",
    "was_translation_needed": true,
    "translation_strategy": "parallel_tier_processing",
    "max_input_tokens": 480,
    "target_chunk_tokens": 300,
    "overlap_tokens": 40,
    "table_content_detected": 0,
    "tier_1_available": true,
    "tier_2_available": true,
    "tier_used": 1,
    "tier_available": true,
    "translation_decision": "tier_1_processing",
    "model_used": "Helsinki-NLP/opus-mt-it-en",
    "quality_scores": {
      "overall": 0.8295032189111535,
      "chunk_count": 2,
      "linguistic": {
        "fluency": 0.7818181818181817,
        "accuracy": 0.8379782379782379,
        "consistency": 0.6173708920187794,
        "completeness": 0.8888971684053651,
        "linguistic_composite": 0.7871925380237548
      },
      "domain_specific": {
        "medical_terminology": 0.5,
        "numerical_integrity": 0.8676470588235294,
        "statistical_terms": 1.0,
        "unit_preservation": 0.5,
        "domain_composite": 0.7102941176470589
      },
      "structural": {
        "format_preservation": 1.0,
        "document_integrity": 1.0,
        "information_architecture": 1.0,
        "structural_composite": 1.0
      },
      "empty_translations": 0,
      "missing_content_ratio": 0.0
    },
    "tier_metadata": {
      "tier": 1,
      "model_loaded": true,
      "model_name": "Helsinki-NLP/opus-mt-it-en",
      "processing_time_seconds": 25.861175,
      "chunks_found": true,
      "total_chunks": 2,
      "chunks_translated": 3,
      "chunks_english": 0,
      "table_chunks_processed": 0,
      "quality_scores": {
        "overall": 0.8295032189111535,
        "chunk_count": 2,
        "linguistic": {
          "fluency": 0.7818181818181817,
          "accuracy": 0.8379782379782379,
          "consistency": 0.6173708920187794,
          "completeness": 0.8888971684053651,
          "linguistic_composite": 0.7871925380237548
        },
        "domain_specific": {
          "medical_terminology": 0.5,
          "numerical_integrity": 0.8676470588235294,
          "statistical_terms": 1.0,
          "unit_preservation": 0.5,
          "domain_composite": 0.7102941176470589
        },
        "structural": {
          "format_preservation": 1.0,
          "document_integrity": 1.0,
          "information_architecture": 1.0,
          "structural_composite": 1.0
        },
        "empty_translations": 0,
        "missing_content_ratio": 0.0
      }
    },
    "total_processing_time_seconds": 244.99639,
    "processing_completed_timestamp": "2025-08-07T13:17:17.296755"
  }
}